Leading the Way in Life Science Technologies

GEN Exclusives

More »

March 15, Vol. 30, No. 6

  • Feature Articles

    • miRNAs' Therapeutic Potential
    • Patricia Fitzpatrick Dimond
    • MicroRNAs (miRNAs) finely regulate gene expression and play an important role in various cellular processes, including cell growth, differentiation, proliferation, and apoptosis To date, more than 5,000 of these endogenous, noncoding single-stranded RNAs have been identified miRNAs act through binding ... more »
    • Oligo Therapeutics Enriching Pipelines
    • Vicki Glaser
    • Market research figures compiled by Agilent Technologies reveal that in 2009, $407 million in direct financing was targeted to the development of oligonucleotide therapeutics in the US This figure represents a combination of publically announced venture capital, private placement, IPO, ... more »
    • Points to Consider in Choosing a CRO
    • Nina Flanagan
    • The pressure to develop new drugs that are best in class within strict budgets has led most pharma and biotech companies to focus on core research and pipeline development, while outsourcing clinical research Since 2001, spending by drug sponsors on ... more »
    • Systems Biology Transforms Vaccine Design
    • Gail Dutton
    • Systems biology is bringing a new, more robust approach to vaccine design that is based upon understanding the molecular network and re-engineering the immune system With this approach, it is within the realm of possibility to develop vaccines against some ... more »
    • Navigating Electronic Submission Pathways
    • Peter Derycz
    • An IND application submitted to the FDA can easily run 10 or more volumes, largely consisting of reviews and copies of published studies related to the drug in question Many of the required documents come from peer-reviewed scholarly literature... more »
  • Columns

    • Exorcising "Sin" from Synthetic Bio
    • Zachary N. Russ
    • Synthetic biology has arrived In recent years, the subject has been bandied about through blogs, on science and opinion pages, and in trade publications and niche magazines across the globe Debaters from every conceivable point of view have hailed it ... more »
    • Cosmix Sets Sights on Next-Generation mAbs
    • Carol Potera
    • Monoclonal antibodies have revolutionized the treatment of many diseases by targeting specific disease-related receptors and pathways However, monoclonal antibodies have shortcomings as well, such as needing to be injected and causing undesirable immune reactions Cosmix Therapeutics is working to make ... more »